Studies on Premenstrual Dysphoria

• Main Author: Eriksson, Olle
• Format: Doctoral Thesis
• Language: English
• Published: Uppsala universitet, Institutionen för kvinnors och barns hälsa 2005
• Subjects: Obstetrics and gynaecology; premenstrual dysphoria; PMDD; premenstrual syndrome; estrogen challenge test; gonadotropin feedback response; LH; FSH; neuroendocrine regulation; buspirone; nefazodone; PCO; testosterone; irritability; depressed mood; bloating; visual analogue scale; VAS; 11C-5-hydroxytryptophan; positron emission tomography; right caudate nucleus; Obstetrik och kvinnosjukdomar; Obstetrics and women's diseases
• Online Access: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5812; http://nbn-resolving.de/urn:isbn:91-554-6260-X

Premenstrual dysphoria, so severe that it affects the lives of the women afflicted, is the condition studied in this thesis. Physiological and pharmacological mechanisms of pathogenetic relevance were investigated. Women with premenstrual dysphoria showed a stronger and less dampened response of LH to an estradiol challenge than asymptomatic women, indicating an altered neuroendocrine regulation. In women with premenstrual dysphoria, the LH response was correlated to the severity of irritability and bloating, and the early FSH response was correlated to the severity of depressed mood. The positron-emission study showed strong, consistent correlations between worsening of mood symptoms and a decrease in brain trapping of the immediate serotonin precursor, from the mid-follicular to the late luteal phase in women with premenstrual dysphoria. The strongest correlations were seen for the cardinal mood symptoms of premenstrual dysphoria, and for their opposites. Physical symptoms showed weaker or no correlations with the exception of nociceptive symptoms from erogenous body regions which showed positive correlations to serotonin precursor trapping in the right caudate nucleus. The findings are consistent with the serotonin hypothesis of premenstrual dysphoria, and might possibly explain the observed effects of serotonin-augmenting drugs in this condition. The partial 5-HT1A receptor agonist buspirone was superior to placebo in the treatment of premenstrual dysphoria. The weak SRI and 5-HT2 receptor antagonist nefazodone was not superior to placebo. For women with premenstrual dysphoria in need of medication and who do not tolerate SRIs because of the sexual sideeffects, buspirone may be an alternative drug, since it had no adverse effects on sexual function. The prevalence of polycystic ovaries and serum levels of androgens were not higher in women with premenstrual dysphoria than in their asymptomatic counterparts. The findings are not consistent with the hypothesis that irritability in women with premenstrual dysphoria is induced by elevated testosterone levels. Thesis results, which are in line with the serotonin hypothesis of premenstrual dysphoria, may imply that increased brain sensitivity is one of the factors underlying severe premenstrual mood symptoms, thereby further supporting a common serotonergic dysregulation in this condition.